Anonymized outcomes from real studies across our sites. Sponsor names and study identifiers stay confidential, always; the numbers speak for themselves. For live operational metrics, see the performance board.
In a Phase 2 study for angiokeratoma, a condition affecting 50,000+ people in the U.S. with no FDA-approved therapy, a Stryde site enrolled and dosed the first patient anywhere in the world. Rare-disease readiness is a speed story: pre-tagged panels and startup discipline made the difference.
In a global lupus study where only three patients had been randomized anywhere, Stryde delivered one of them. Lupus randomization is among the hardest milestones in clinical research; execution at the coordinator and recruitment level is what gets a site there.
First patient randomized in a trial of a new injection-based skin cancer treatment, pointing toward a less invasive option for patients cycling through repeated procedures. Sourced from the practice's own panel, no recruitment campaign required.
Preliminary feasibility from real tagged patient counts in 48 business hours, guaranteed and tracked.